FGF2 and neoplasm: Among these combinations, the co-treatment with PD98059 or U0126 and LY294002 impaired migration, tumor cells invasion and tumor angiogenesis (64,74–76), associated with decrease of matrix metalloproteinase-2 (MMP2), inhibition of vascular-endothelial growth factor (VEGF) secretion and expression, and strong decrease of both basic fibroblast growth factor (bFGF) and HIF-1α (74–76).